NCT00610649View on ClinicalTrials.gov

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 20, 2007

Primary Completion Date

November 18, 2008

Study Completion Date

December 10, 2008

Conditions
Depression
Interventions
DRUG

MK-8777

Orally administered capsules containing either 50 mg or 100 mg MK-8777.

DRUG

Placebo

Orally administered matching placebo capsules.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00610649 - Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001) | Biotech Hunter | Biotech Hunter